Myth and Truth in Opioid Consumption with Intrathecal Morphine Pump Implantation in Chronic Pain: A Retrospective Cohort Study with Claims Database in South Korea
Pain Medicine · 2023
DOI: 10.1093/pm/pnac110 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Pain Medicine, 2023. Verfasst von Yongjae Yoo und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Analgesics, Opioid, Chronic Pain. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 44 Literaturangaben. Gefördert von: Korean National Health Insurance Service.
Themen: Schmerzmanagement
Abstract (Originalsprache)
Objective
To investigate the opioid consumption and the healthcare resource utilization in patients with the intrathecal drug delivery system (IDDS) therapy and the comprehensive medical management (CMM) alone.
Design
A retrospective cohort study with a customized claims database.
Setting
In a university-based hospital. Subjects Patients with complex regional pain syndrome, post-laminectomy syndrome, and fibromyalgia.
Methods
Using propensity score matching (1:3), we selected patients with morphine infusion through IDDS (IDDS group) and CMM alone (CMM group). The primary endpoints were comparisons of average morphine equivalents daily dosages (MEDD, mg/day) for 6 and 12 months from an index date. The number of emergency room (ER) visits and hospitalizations and the total medical expenditures were compared as secondary outcomes.
Results
In total, 82 patients (N = 23 in the IDDS group and N = 59 in the CMM group) were analyzed. Although a 6-month average MEDD did not reach statistical significance, a 12-month average MEDD was significantly decreased in the IDDS group compared to the CMM group (53.2 ± 46.3 vs 123.9 ± 176.4, respectively; P = 0.008). ER visits were more frequent in the IDDS group than the CMM group at baseline (5.4 vs 0.5, respectively; P = .002), which was maintained for 12 months (P < 0.001). Otherwise, the number of hospitalization and the medical expenditures for pain management were not different between the groups for 12 months.
Conclusions
The combined IDDS therapy had some benefits in reducing opioid consumption for 1-year follow-up compared to the CMM alone in chronic noncancer pain patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Anesthesiology and Pain Medicine, Seoul National University Hospital, Seoul, Republic of Korea.
- Department of Anesthesiology and Pain Medicine, Boramae Medical Center, Seoul, Republic of Korea.
- Healthcare Economics and Government Affairs, Medtronic Korea, Inc., Seoul, Republic of Korea.
- Department of Health Convergence, Ewha Womans University, Seoul, Republic of Korea.
- Georgetown University School of Medicine, Washington, DC, USA.
- Department of Anesthesiology and Pain Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea.
ORCID-Profile: Jee Youn Moon
Förderung
- Korean National Health Insurance Service
Zitieren
APA
Yoo, Y., Oh, J. H., Lee, H., Choi, H., Joo, S., Han, A. H., & Moon, J. Y. (2023). Myth and Truth in Opioid Consumption with Intrathecal Morphine Pump Implantation in Chronic Pain: A Retrospective Cohort Study with Claims Database in South Korea. Pain Medicine. https://doi.org/10.1093/pm/pnac110
Vancouver
Yoo Y, Oh JH, Lee H, Choi H, Joo S, Han AH, et al. Myth and Truth in Opioid Consumption with Intrathecal Morphine Pump Implantation in Chronic Pain: A Retrospective Cohort Study with Claims Database in South Korea. Pain Medicine. 2023. doi:10.1093/pm/pnac110
BibTeX
@article{Yoo2023,
author = {Yoo, Yongjae and Oh, Joo Hyeon and Lee, Haine and Choi, Hyunsook and Joo, Somin and Han, Andrew Hogyu and Moon, Jee Youn},
title = {Myth and Truth in Opioid Consumption with Intrathecal Morphine Pump Implantation in Chronic Pain: A Retrospective Cohort Study with Claims Database in South Korea},
journal = {Pain Medicine},
year = {2023},
doi = {10.1093/pm/pnac110}
}
EUVIMED